Micro-elimination of hepatitis C virus.
World Health Organization
direct-acting antivirals
elimination
hepatitis C virus
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
26
12
2019
accepted:
27
12
2019
entrez:
21
2
2020
pubmed:
23
2
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
HCV affects about 71 million people worldwide with 1.75 million new infections a year, mainly associated with healthcare, blood transfusion before screening of donors and drug use. Hepatitis C is a systemic disease with hepatic and extrahepatic manifestations resulting in increased morbidity and mortality in HCV-infected patients compared to cured or uninfected individuals. The goal of eliminating hepatitis C by 2030 is based on the following three main actions: strengthening and increasing outreach screening; increasing access to treatment; and improving prevention. Although the tools and the targets of HCV elimination have now been well established, micro-elimination, a cure in high-risk populations, is possible, but has not been achieved. These populations are mainly migrants, prisoners, drug users, HIV co-infected patients and psychiatric patients. New tools must be developed to achieve micro-elimination, in particular, rapid diagnostic orientation tests for better screening, delocalization of healthcare services to improve access to care, and training physicians to raise awareness of the disease, increase understanding of its pathogenesis and provide information on the availability of safe and effective treatment to cure chronic infection and reverse hepatic and extrahepatic manifestations. Thus, while the goal of complete elimination of hepatitis C virus was feasible in Western countries, it was more difficult in high-prevalence countries where improvement in the detection of chronic infection (with rapid serological and virological diagnostic tests), outsourcing of diagnostic and therapeutic care and access to direct oral antivirals are urgently needed.
Sections du résumé
BACKGROUND & AIMS
HCV affects about 71 million people worldwide with 1.75 million new infections a year, mainly associated with healthcare, blood transfusion before screening of donors and drug use. Hepatitis C is a systemic disease with hepatic and extrahepatic manifestations resulting in increased morbidity and mortality in HCV-infected patients compared to cured or uninfected individuals.
RESULTS
The goal of eliminating hepatitis C by 2030 is based on the following three main actions: strengthening and increasing outreach screening; increasing access to treatment; and improving prevention. Although the tools and the targets of HCV elimination have now been well established, micro-elimination, a cure in high-risk populations, is possible, but has not been achieved. These populations are mainly migrants, prisoners, drug users, HIV co-infected patients and psychiatric patients. New tools must be developed to achieve micro-elimination, in particular, rapid diagnostic orientation tests for better screening, delocalization of healthcare services to improve access to care, and training physicians to raise awareness of the disease, increase understanding of its pathogenesis and provide information on the availability of safe and effective treatment to cure chronic infection and reverse hepatic and extrahepatic manifestations.
CONCLUSION
Thus, while the goal of complete elimination of hepatitis C virus was feasible in Western countries, it was more difficult in high-prevalence countries where improvement in the detection of chronic infection (with rapid serological and virological diagnostic tests), outsourcing of diagnostic and therapeutic care and access to direct oral antivirals are urgently needed.
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
67-71Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081-1088.
Assembly WHOS-NWH. Draft Global Health Sector Strategies Viral Hepatitis 2016-2021, 2016. http://www.who.int/hepatitis/strategy2016-2021/Draft_global_health_sector_strategy_viral_hepatitis_13nov.pdf.
http://www.who.int/news-room/detail/27-07-2017-eliminate-hepatitis-who Organization WH. Global hepatitis report. Geneva, 2017.
Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2015;2017(2):161-176.
Trinchet J-C, Bourcier V, Chaffaut C, et al. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology. 2015;62:737-750.
Negro F, Forton D, Craxì A, et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149:1345-1360.
Pozzato G, Mazzaro C, Dal Maso L, et al. Hepatitis C virus and non-Hodgkin's lymphomas: meta-analysis of epidemiology data and therapy options. World J Hepatol. 2016;8:107-116.
Pol S, Vallet-Pichard A, Hermine O. Extra-hepatic cancers and HCV. Nat Rev Gastroenterol Hepatol. 2018;15:283-290.
Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469-477.
Nahon P, Bourcier V, Layese R, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017;152:142-156.
Carrat F, Fontaine H, Dorival C, et al.;for the AFEF/ANRS Hepather CO22 Cohort. Clinical outcomes in patients with chronic hepatitis C following direct-acting antiviral therapy: a prospective cohort study. Lancet. 2019;393:1453-1464.
Liang TJ, Ghany MG. Therapy of hepatitis C-back to the future. N Engl J Med. 2014;22:2043-2047.
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153-194.
European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(5):325-336.15.
Llibre A, Shimakawa Y, Mottez E, et al. Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus. Gut. 2018;67(11):2017-2024.
Lazarus JV, Safreed-Harmon K, Hetherington KL, et al. Health outcomes for clients of needle and syringe programs in prisons. Epidemiol Rev. 2018;40:96-104.
Bielen R, Stumo SR, Halford R, et al. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries. Harm Reduct. J. 2018;15(25):18.
Grebely J, Dore GJ, Alami NN, et al. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. Int J Drug Policy. 2019;66:73-79.
Yaya I, Roux P, Marcellin F, et al. Evolution of patients' socio-behavioral characteristics in the context of DAA: results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients. PLoS ONE. 2018;13(7):e0199874.
Boerekamp A, van den Berk GE, Lauw FN, et al. Declining hepatitis C virus (HCV) incidence in Dutch human immunodeficiency virus-positive men who have sex with men after unrestricted access to HCV therapy. Clin Infect Dis. 2018;66:1360-1365.
Osmond DH, Charlebois E, Sheppard HW, et al. Comparison of risk factors for hepatitis C and hepatitis B virus infection in homosexual men. J Infect Dis. 1993;167(1):66-71.
Terrault NA, Dodge JL, Murphy EL, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013;57(3):881-889.
Wandeler G, Dufour JF, Bruggmann P, Rauch A. Hepatitis C: a changing epidemic. Swiss Med Wkly. 2015;145:1-9.
van de Laar TJW, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS. 2010;24(12):1799-1812.
Danta M, Rodger AJ. Transmission of HCV in HIV-positive populations. Curr Opin HIV AIDS. 2011;6(6):451-458.
McFaul K, Maghlaoui A, Nzuruba M, et al. Acute hepatitis C infection in HIV-negative men who have sex with men. J Viral Hepat. 2015;22(6):535-538.
Lazarus JV, Wiktor S, Colombo M, Thursz M; on behalf of the EASL International Liver Fundation. Micro-elimination - a path to global elimination of hepatitis C. J Hepatol. 2017;67:665-666.
Piroth L, Wittkop L, Lacombe K, et al. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort. J Hepatol. 2017;67(1):23-31.
Colombo M, Aghemo A, Liu H, et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med. 2017;166(2):109-117.
Gordon CE, Berenguer MC, Doss W, et al. Prevention, diagnosis, evaluation, and treatment of hepatitis C virus infection in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2018 clinical practice guideline. Ann Intern Med. 2019. https://doi.org/10.7326/M19-1539.
Goodkin K. Assessing the prevalence of HIV, HBV, and HCV infection among people with severe mental illness. Lancet Psychiatry. 2016;3:40-48.
Dinwiddie SH, Shicker L, Newman T. Prevalence of hepatitis C among psychiatric patients in the public sector. Am J Psychiatry. 2003;160:172-174.